Pancreatic Cancer Research

ResearcherHallym UniversityActive in the last 2 years

Dae Young Zang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2602-7848; OpenAlex author ID A5084870834, A5105424865. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 7

  1. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  2. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Co-author DOI 10.1016/j.ejca.2021.08.002↗
  3. Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients. Co-author DOI 10.1159/000517245↗
  4. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. Last author DOI 10.7150/jca.50514↗
  5. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1038/s41598-019-53271-6↗
  6. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Last author DOI 10.1007/s00280-013-2265-z↗
  7. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysi… Co-author DOI 10.1007/s10637-011-9651-3↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joo Young Jung · 2 shared papers, 2013–2021 · strength 0.19
  2. Zev A. Wainberg · 1 shared paper, 2024 · strength 0.18
  3. Choong‐kun Lee · 1 shared paper, 2024 · strength 0.18
  4. Hye Jin Choi · 1 shared paper, 2024 · strength 0.18
  5. Hyehyun Jeong · 1 shared paper, 2024 · strength 0.18
  6. Kyu‐pyo Kim · 1 shared paper, 2024 · strength 0.18
  7. Do Hyun Park · 1 shared paper, 2024 · strength 0.18
  8. Tae Jun Song · 1 shared paper, 2024 · strength 0.18
  9. Sung‐Hoon Moon · 1 shared paper, 2024 · strength 0.18
  10. Inkeun Park · 1 shared paper, 2024 · strength 0.18
  11. Baek‐Yeol Ryoo · 1 shared paper, 2024 · strength 0.18
  12. Changhoon Yoo · 1 shared paper, 2024 · strength 0.18
  13. Dongwook Oh · 1 shared paper, 2024 · strength 0.18
  14. Hyun Ae Jung · 1 shared paper, 2021 · strength 0.16
  15. Hunho Song · 2 shared papers, 2013–2021 · strength 0.14
  16. Boram Han · 2 shared papers, 2013–2021 · strength 0.14
  17. Jung Han Kim · 2 shared papers, 2013–2021 · strength 0.14
  18. Jin Won Kim · 1 shared paper, 2021 · strength 0.11
  19. Byoung Yong Shim · 1 shared paper, 2021 · strength 0.11
  20. Jung Hun Kang · 1 shared paper, 2021 · strength 0.11
  21. Jung Hoon Kim · 1 shared paper, 2021 · strength 0.11
  22. Se‐Il Go · 1 shared paper, 2021 · strength 0.11
  23. In Gyu Hwang · 1 shared paper, 2021 · strength 0.11
  24. Woo Kyun Bae · 1 shared paper, 2021 · strength 0.11
  25. Jun Ho Ji · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.